7 TH EUROPEAN SCHOOL OF DERMATO-ONCOLOGY: UPDATE ON CUTANEOUS ONCOLOGY (ESDO) JANUARY 17 th 19 th, 2019

Transcription

1 Course Directors Petr Arenberger, Prague, Czech Republic Claus Garbe, Tuebingen, Germany Axel Hauschild, Kiel, Germany Christoph Höller, Vienna, Austria 7 TH EUROPEAN SCHOOL OF DERMATO-ONCOLOGY: UPDATE ON CUTANEOUS ONCOLOGY (ESDO) JANUARY 17 th 19 th, 2019 NOVOTEL BERLIN AM TIERGARTEN BERLIN, GERMANY Preliminary Program (update 09/07/2018)

2

3 1 Content European Association of Dermato-Oncology (EADO) 2 Target Audience 2 Educational Objectives 2 Course Organization 3 Program Overview 4 Program 6 Thursday, January 17 th, Friday, January 18 th, Saturday, January 19 th, Course Faculty 11 General Information 14 Sponsors 17

4 2 European Association of Dermato-Oncology (EADO) The EADO is a non-profit organization funded in 1999 to promote, coordinate and improve clinical and laboratory research activities in the field of skin cancer including primary and secondary prevention, early detection, clinical diagnosis and clinical and experimental research. EADO has organized many successful meetings and the upcoming ones are visible on the website ( The EADO initiates for the sixth time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of locoregional disease and distant metastatic disease. Target Audience This 2,5-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course. Educational Objectives The principal aim of the course is to provide a comprehensive and detailed understanding of the decision-making process for the management of all types and stages of skin cancer. This will include diagnosis and primary treatment, management of locoregional disease and distant metastatic disease, and adjuvant treatment. This is particularly relevant given the rapid progress in our understanding of melanoma and non-melanoma skin cancer, and the development of new treatments. In particular delegates will acquire the following knowledge: 1. Strategies for diagnosis of melanoma, Merkel cell and non-melanoma skin cancer including dermoscopy and confocal laser microscopy. 2. The indications, risks and benefits and strategies for mole screening. 3. Diagnosis of skin cancer: how to break bad news. 4. The indications and methods for genetic diagnosis and genetic counseling of skin cancer patients. 5. The present AJCC staging systems and how to stage melanoma, Merkel cell and cutaneous squamous cell carcinoma, and other non-melanoma skin cancers.

5 3 6. The value of imaging and biomarkers for the detection of metastases and disease staging. 7. Adjuvant treatment of skin cancer: radiotherapy, immunotherapy, chemotherapy. 8. New systemic treatments for stage IV melanoma: targeted agents and immunotherapeutics. 9. New treatment options of advanced basal cell carcinoma. 10. New systemic treatments for advanced Merkel cell and squamous cell carcinoma. 11. The characteristics of mucosal and uveal melanomas and their treatment options. 12. Options for topical treatment of epithelial skin cancers. 13. The current classification of cutaneous lymphoma, staging and treatment options for different subtypes of cutaneous lymphoma. 14. Clinical trials in skin cancer: an update. 15. The indications and strategies for supportive treatments including best supportive care. Course Organization The course consists of plenary sessions and interactive outbreak sessions. Plenary sessions will comprise clear structured and up-to-date presentations followed by audience discussion. Voting devices will be used to respond to multiple choice questions. These questions may precede the presentation of the structured knowledge or may be presented at the end in order to test the level of knowledge the audience has gained. The main part of the course consists of 8 interactive sessions, each with no more than 30 attendants. Every participant takes part in each of these sessions which mainly comprise casebased discussion. These will be used to illustrate treatment pathways, how risk and benefit are assessed, and how management decisions are made. We look forward to welcoming you in Berlin in January 2019! Petr Arenberger, MD Claus Garbe, MD Axel Hauschild, MD Christoph Höller, MD Course Directors

6 4 Program Overview A commercial exhibition will be held on all days close to the meeting rooms. Thursday January 17 th, :00 9:00 10:00 11:00 12:00 Group I Group II Group III Group IV Lectures: Kurland 2+3 Course A+E: Kurland 1 Course B+F: Kurland 2 Course C+G: Kurland 3 Course D+H: Berlin-Ceres All meeting rooms are located on the ground floor. Friday January 18 th, 2019 Group I Group II Group III Group IV PLENARY SESSION 2 C. Garbe A. Hauschild C. Höller C. Robert Break COURSE C C. Höller COURSE D C. Lebbé COURSE A R. Kaufmann COURSE B A. Stratigos Break COURSE D C. Lebbé COURSE A R. Kaufmann COURSE B A. Stratigos COURSE C C. Höller Lunch Saturday January 19 th, 2019 Group I Group II Group III Group IV COURSE G F. Overkamp COURSE H R. Dummer COURSE E M. Volkenandt COURSE F C. Garbe Break COURSE H R. Dummer COURSE E M. Volkenandt COURSE F C. Garbe COURSE G F. Overkamp Break PLENARY SESSION 4 M. Weichenthal L. K. Seculovic P. Arenberger I. Zalaudek

7 5 13:00 14:00 15:00 16:00 17:00 18:00 Welcome Session PLENARY SESSION 1 J. J. Grob P. Mohr M. Arenbergerova I. Zalaudek Break COURSE A R. Kaufmann COURSE B A. Stratigos COURSE C C. Höller COURSE D C. Lebbé Break COURSE B A. Stratigos COURSE C C. Höller COURSE D C. Lebbé COURSE A R. Kaufmann CUTANEOUS SIDE EFFECTS PLENARY TREATMENT SESSION 3 J. OPTIONS Malvehy P. Arenberger S. P. Sardȧ L. Thomas Break COURSE E M. Volkenandt COURSE F C. Garbe COURSE G F. Overkamp COURSE H R. DUMMER Break COURSE F C. Garbe COURSE G F. Overkamp COURSE H R. DUMMER COURSE E M. Volkenandt EXAMINATIONS: EUROPEAN CERTIFICATE FOR MEDICAL TUMOR THERAPY IN DERMATOONCOLOGY

8 6 Program Thursday, January 17 th, :45 14:00 Welcome and course introduction Claus Garbe, Tuebingen, Germany PLENARY SESSION 1: Screening and early detection Chairperson: Ana Maria Forsea and Monika Arenbergerova 14:00 14:20 LECTURE 1: Epidemiology of skin cancer Kurland 2+3 Jean Jacques Grob, Marseille, France 14:20 14:40 LECTURE 2: Skin cancer screening: Fact or fiction Kurland 2+3 Peter Mohr, Buxtehude, Germany 14:40 15:00 LECTURE 3: Dermoscopy of melanocytic skin cancers Kurland 2+3 (with quiz questions) Monika Arenbergerova, Prague, Czech Republic 15:00 15:20 LECTURE 4: Dermoscopy of non-melanocytic skin cancers Kurland 2+3 (with quiz questions) Iris Zalaudek, Trieste, Italy 15:20 15:30 Discussion 15:30 16:00 Coffee Break 16:00 17:00 COURSE A: Paraneoplastic syndromes Group I Kurland 1 Roland Kaufmann, Frankfurt, Germany 16:00 17:00 COURSE B: Treatment of actinic keratosis and field cancerization Group II Kurland 2 Alexander Stratigos, Athens, Greece 16:00 17:00 COURSE C: Intralesional tumor treatments Group III Kurland 3 Christoph Höller, Vienna, Austria 16:00 17:00 COURSE D: Common and rare adverse Group IV Berlin-Ceres events of checkpoints inhibitors and targeted therapies Celeste Lebbé, Paris, France 17:00 17:30 Coffee Break

9 7 17:30 18:30 COURSE B: Treatment of actinic keratosis and field cancerization Group I Kurland 2 Alexander Stratigos, Athens, Greece 17:30 18:30 COURSE C: Intralesional tumor treatments Group II Kurland 3 Christoph Höller, Vienna, Austria 17:30 18:30 COURSE D: Common and rare adverse Group III Berlin-Ceres events of checkpoints inhibitors and targeted therapies Celeste Lebbé, Paris, France 17:30 18:30 COURSE A: Paraneoplastic syndromes Group IV Kurland 1 Roland Kaufmann, Frankfurt, Germany Friday, January 18 th, 2019 PLENARY SESSION 2: Guidelines for melanoma management and case discussions Chairperson: Roland Kaufmann and Christoph Höller 08:00 08:20 LECTURE 5: Mutational testing Kurland 2+3 Claus Garbe, Tuebingen, Germany 08:20 08:40 LECTURE 6: Adjuvant therapies for high risk melanoma Kurland 2+3 Axel Hauschild, Kiel, Germany 08:40 09:00 LECTURE 7: Targeted therapy of metastatic melanoma Kurland 2+3 Christoph Höller, Vienna, Austria 09:00 09:20 LECTURE 8: Immune checkpoint inhibition Kurland 2+3 Caroline Robert, Paris, France 09:20 09:30 Discussion

10 8 09:30 10:00 Coffee Break 10:00 11:00 COURSE C: Intralesional tumor treatments Group I Kurland 3 Christoph Höller, Vienna, Austria 10:00 11:00 COURSE D: Common and rare adverse Group II Berlin-Ceres events of checkpoints inhibitors and targeted therapies Celeste Lebbé, Paris, France 10:00 11:00 COURSE A: Paraneoplastic syndromes Group III Kurland 1 Roland Kaufmann, Frankfurt, Germany 10:00 11:00 COURSE B: Treatment of actinic keratosis and field cancerization Group IV Kurland 2 Alexander Stratigos, Athens, Greece 11:00 11:30 Coffee Break 11:30 12:30 COURSE D: Common and rare adverse Group I Berlin-Ceres events of checkpoints inhibitors and targeted therapies Celeste Lebbé, Paris, France 11:30 12:30 COURSE A: Paraneoplastic syndromes Group II Kurland 1 Roland Kaufmann, Frankfurt, Germany 11:30 12:30 COURSE B: Treatment of actinic keratosis and field cancerization Group III Kurland 2 Alexander Stratigos, Athens, Greece 11:30 12:30 COURSE C: Intralesional tumor treatments Group IV Kurland 3 Christoph Höller, Vienna, Austria 12:30 13:00 Lunch PLENARY SESSION 3: Melanoma diagnostics and follow-up Chairperson: Susanna Puig and Petr Arenberger 13:00 13:30 LECTURE 9: New diagnostic devices Kurland 2+3 Josep Malvehy, Barcelona, Spain 13:30-14:00 LECTURE 10: Follow-up of melanoma and Kurland 2+3 non-melanoma skin cancer Petr Arenberger, Prague, Czech Republic

11 9 14:00 14:30 LECTURE 11: Dermoscopy of facial lesions Kurland 2+3 Susana Puig Sardá, Barcelona, Spain 14:30 15:00 LECTURE 12: Dermoscopy of acral lesions Kurland 2+3 Luc Thomas, Lyon, France 15:00 15:30 Coffee Break 15:30 16:30 COURSE E: Systemic treatment of non-melanoma skin cancer Group I Kurland 1 Axel Hauschild, Kiel, Germany 15:30 16:30 COURSE F: Excisional, incisional and shave biopsies: How I do it Group II Kurland 2 Claus Garbe, Tuebingen, Germany 15:30 16:30 COURSE G: The new oncologic drugs: their mode of action Group III Kurland 3 Olivier Michielin, Lausanne, Switzerland 15:30 16:30 COURSE H: Cutaneous lymphomas Group IV Berlin-Ceres Emmanuela Guenova, Zurich, Switzerland 16:30 16:45 Coffee Break 16:45 17:45 COURSE F: Excisional, incisional and shave biopsies: How I do it Group I Kurland 2 Claus Garbe, Tuebingen, Germany 16:45 17:45 COURSE G: The new oncologic drugs: their mode of action Group II Kurland 3 Olivier Michielin, Lausanne, Switzerland 16:45 17:45 COURSE H: Cutaneous lymphomas Group III Berlin-Ceres Emmanuela Guenova, Zurich, Switzerland 16:45 17:45 COURSE E: Systemic treatment of non-melanoma skin cancer Group IV Kurland 1 Axel Hauschild, Kiel, Germany

12 10 Saturday, January 19 th, :30 09:30 COURSE G: The new oncologic drugs: their mode of action Group I Kurland 3 Olivier Michielin, Lausanne, Switzerland 08:30 09:30 COURSE H: Cutaneous lymphomas Group II Berlin-Ceres Emmanuela Guenova, Zurich, Switzerland 08:30 09:30 COURSE E: Systemic treatment of non-melanoma skin cancer Group III Kurland 1 Axel Hauschild, Kiel, Germany 08:30 09:30 COURSE F: Excisional, incisional and shave biopsies: How I do it Group IV Kurland 2 Claus Garbe, Tuebingen, Germany 09:30 10:00 Coffee Break 10:00 11:00 COURSE H: Cutaneous lymphomas Group I Berlin-Ceres Emmanuela Guenova, Zurich, Switzerland 10:00 11:00 COURSE E: Systemic treatment of non-melanoma skin cancer Group II Kurland 1 Axel Hauschild, Kiel, Germany 10:00 11:00 COURSE F: Excisional, incisional and shave biopsies: How I do it Group III Kurland 2 Claus Garbe, Tuebingen, Germany 10:00 11:00 COURSE G: The new oncologic drugs: their mode of action Group IV Kurland 3 Olivier Michielin, Lausanne, Switzerland 11:00 11:30 Coffee Break PLENARY SESSION 4: HOT TOPICS IN DERMATOONCOLOGY Chairperson: Lidija Kandolf Sekulovic and Iris Zalaudek 11:30 12:00 LECTURE 13: The new AJCC classification for melanoma 2018 Kurland 2+3 Michael Weichenthal, Kiel, Germany 12:00 12:30 LECTURE 14: Management of mucosal and ocular melanomas Kurland 2+3 Lidija Kandolf Sekulovic, Belgrade, Serbia 12:30 13:00 LECTURE 15: Rare skin cancers: interactive quiz Kurland 2+3 Petr Arenberger, Prague, Czech Republic 13:00 13:30 LECTURE 16: Dermoscopy Quiz Kurland 2+3 Iris Zalaudek, Trieste, Italy 13:30 14:00 Lunchbags 14:00 17:00 Examinations: European Certificate for Medical Tumor Therapy in Dermatooncology

13 11 Invited Course Faculty A Petr Arenberger, MD Professor of Dermatology, Director Charles University 3rd School of Medicine Srobarova 50 CZ Prague, Czech Republic Phone: avemedica@ .cz Monika Arenbergerova, MD Department of Dermatovenereology, Third Faculty of Medicine Charles University in Prague Czech Republic arenbergerova(a) .cz F Ana-Maria Forsea, MD Assistant Professor for Dermatology Carol Davila University of Medicine and Pharmacy Bucharest Bulevardul Eroii Sanitari Bucharest, Romania Phone: aforsea@yahoo.com G Claus Garbe, MD Professor of Dermatology Eberhard Karls University Liebermeister Str Tuebingen, Germany Phone: claus.garbe@med.uni-tuebingen.de Jean Jacques Grob, MD Professor of Dermatology Service de Dermatology and Cancer Research Hôpital de la Timone 264 Rue St. Pierre Marseille, France Phone: jean-jacques.grob@ap-hm.fr Emmanuela Guenova, MD University of Zurich Hospital Gloriastrasse Zurich Switzerland Phone: Emmanuella.Guenova@usz.ch

14 12 H Axel Hauschild, MD Professor of Dermatology University of Kiel Rosalind-Franklin-Str Kiel, Germany Phone: ahauschild@dermatology.uni-kiel.de Christoph Höller, MD Professor of Dermatology Medical University of Vienna Waehringer Guertel Vienna, Austria Phone: christoph.hoeller@meduniwien. ac.at K Lidija Kandolf Sekulovic, MD Professor of Dermatology Medical Faculty Military Medical Academy Crnotravska Belgrade, Serbia Phone: lkandolfsekulovic@gmail.com Roland Kaufmann, MD Professor of Dermatology, Director Clinical Center J. W. Goethe University Theodor-Stern-Kai Frankfurt/Main, Germany Phone: kaufmann@em.uni-frankfurt.de L Celeste Lebbé, MD Professor of Dermatology Hôpital Saint-Louis 1, Avenue Claude-Vellefaux Paris, France Phone: celeste.lebbe@aphp.fr M Josep Malvehy, MD Director of the Melanoma Unit Hospital Clinic of Barcelona C/Villarroel Barcelona, Spain Phone: jmalvehy@clinic.ub.es Olivier Michielin, MD Head of Melanoma Clinic Department of Oncology Swiss Institute of Bioinformatics Ludwig Institute 1015 Lausanne Switzerland Phone: Olivier.Michielin@chuv.ch Peter Mohr, MD Center of Dermatology Elbe Klinikum Buxtehude Am Krankenhaus Buxtehude Germany Phone: / peter.mohr@elbekliniken.de

15 13 P Susana Puig Sardá, MD Hospital Clinic of Barcelona C/Villarroel 170 Barcelona, Spain Phone: susipuig@gmail.com R Caroline Robert, MD Head Dermatology Gustave Roussy Institute 114 rue Edouard Vaillant Villejuif, France Phone: caroline.robert@gustaveroussy.fr S W Michael Weichenthal, MD Professor of Dermatology University of Kiel Rosalind-Franklin-Str Kiel, Germany Phone: mweichenthal@dermatology. uni-kiel.de Z Iris Zalaudek, MD Head of the Dermatology Clinic University of Trieste Hospital Maggiore Piazza dell' Ospedale Trieste, Italy iris.zalaudek@gmail.com Alexander Stratigos, MD University of Athens School of Medicine Andreas Sygros Hospital 5 Dragoumi Street Athens , Greece Phone: alstrat2@gmail.com T Luc Thomas, MD Centre hospitalier Lyon sud 165 Chemin DU GRAND REVOYET PIERRE-BENITE luc.thomas@chu-lyon.fr

16 14 General Information Cancellation Policy Cancellations must be received in writing by December 20, No refunds will be granted after that date. A processing fee of 30 Euro will be deducted from each cancelled registration. Substitutions are possible. To substitute a registration, please send an including the name of the original registrant and the name of the person substituting to info@medconcept.org. The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force, or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso. CME Credits An application for CME accreditation will be made. How to receive your CME Credits To obtain CME credits, please fill in the evaluation forms, which you will find in your course bag. To get your certificate of attendance with the CME credits please return the evaluation forms duly filled in to the registration desk. Course Organization MedConcept Gesellschaft für medizinische Projekte mbh Friedenstraße Neuenhagen b. Berlin, Germany Phone: +49 (0) Fax: +49 (0) info@medconcept.org

17 15 Course Venue Novotel Berlin am Tiergarten Strasse des 17. Juni Berlin, Germany Phone: +49 (0) European Certificate for Medical Tumor Therapy in Dermatooncology Definition: The advanced continuing medical education training in "Medical Tumor Therapy in Dermatooncology" is intended as an addition to the specialist dermatologist's competence, and covers the administration and monitoring of medical therapy of patients with malignant skin tumors, including supportive measures and management of complications and side-effects from therapy. Training Goal: The aim of the continuing education training program is to obtain the professional competence in systemic therapy for skin cancers after completing the required training period. The competence will be certified by the European Certificate for Medical Tumor Therapy in Dermatooncology awarded by EADO in collaboration with UEMS. Prerequisites for candidates: Certification of specialist in dermatology by the relevant national authority (Board Certification) Completion of training program (12 months involved in direct patients care) Attendance of at least one ESDO course Examination by the EADO Board Certification in Dermato-Oncology For further information please contact Mr. Christopher Huhn at Exhibition Opening Hours Thursday, January 17: 13:00 18:30 Friday, January 18: 07:30 18:00 Saturday, January 19: 08:00 13:30

18 16 Fees Registration Fee of 380 Euro (incl. VAT) covers Admission to scientific sessions Welcome reception Admission to exhibition Coffee breaks and lunch Bag with course documents Certificate of attendance Language and Translation The official language of the meeting will be English. Simultaneous translation will not be provided. Registration / Information Desk The registration desk is situated at the ground floor of the Novotel Berlin am Tiergarten. Opening hours Thursday, January 17: 12:00 19:00 Friday, January 18: 07:30 18:00 Saturday, January 19: 08:00 14:00 Sustainability MedConcept is internally working on increasing its sustainability efforts and we would like to encourage all involved in the 7 th European School of Dermato-Oncology Meeting to minimize their environmental and social impacts. Ways to get involved: Travel by train or carbon offsetting your flights to Berlin and encourage your colleagues to do the same If travelling by car, car pool with your colleagues Use the recycling bins provided on-site Recycle your name-badge in the bin provided at the registration desk Recycle all brochures and promotional items not needed in the bin provided within the industrial exhibition Use the public transportation system in Berlin

19 17 Registration Form 7 th European School of Dermato-Oncology January 17 th 19 th, 2019 Novotel Berlin am Tiergarten Berlin, Germany First Name: Last Name: Professional Title: Degree: MD PhD RN PA-C Gender: Male Female Speciality: Institution: Address: City: Zip Code: Country: Phone: Fax: Fees Registration Fee of 380,00 Euro (incl. VAT) covers Admission to scientific sessions Admission to exhibition Bag with course documents Welcome reception Coffee breaks and lunch Certificate of Attendance Payment Method Bank Transfer: Registration can only be confirmed upon receipt of full payment. Credit Card: MasterCard Visa American Express Credit Card Number: Expiration Date: Security Code CCV: (MC/Visa 3 digits on back, AMEX 4 digits on front) Cardholder Name: Signature: An invoice will be send by to the given address. If the invoice address is different from the address given above, please send an including the name of the registrant and the full invoice address to mirja.christ@medconcept.org. By completing the registration form, the participant accepts the general terms and conditions as well as the cancellation policy given on the congress website at and agrees that his/her data may be used, processed and published (e.g. within the list of participants) for organizational purposes of the event. The participant accepts that MedConcept will contact him/her by for organizational matters (e.g. the registration confirmation and invoice) and information related to the event. I accept until further notice that MedConcept will inform me about future events by . To Register Mail registration form to: MedConcept GmbH, Friedenstraße 58, Neuenhagen bei Berlin, Germany Fax registration form to: +49 (0) Register online: